← Leaderboards

Robert C. Green

Boston University Medical Campus

Google Scholar ↗PubMed ↗ORCID ↗

$38,307,859

Attributed

$70,604,647

Total exposure

37

Grants

29

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $14.4M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$76,716,325 · 38

By mechanism

OT2$24,099,393 · 2

R01$18,575,559 · 4

U01$16,645,853 · 2

U19$6,255,853 · 3

RF1$5,998,025 · 1

P30$3,182,059 · 1

Top collaborators

Most similar at Boston University Medical Campus

Same institution · by research overlap

Alpaslan Dedeoglu$7,018,151
Lindsay A. Farrer$55,579,906
Sudha Seshadri$50,696,682
Daniel Cifuentes$3,510,042

Others in their field

Top investigators on “Alzheimer&Apos”

Jose A Luchsinger · Columbia University Health Sciences$56,595,040
Eric M Reiman · Banner Health$48,982,487
Yadong Huang · J. David Gladstone Institutes$40,311,515
Lindsay A. Farrer · Boston University Medical Campus$34,189,802
David M Holtzman · Washington University$28,985,806
Michael W Weiner · Northern California Institute Res &Educ$28,197,224

Research focus

Alzheimer&AposEnrollmentFundingProtocols DocumentationParticipantClinical TrialsFutureS DiseaseRandomizedResourcesDisclosureGenomicsResearch PersonnelUnited States National Institutes Of HealthFamilyProgramsAfrican AmericanPsychological ImpactMedicalReportingGenotypeGenome SequencingBaseClinical Practice

Grant awards (94)

Feasibility of Genomic Newborn Screening Through Public Health Laboratories$14,399,393

OT2 · FY2025 · OD · contact PI

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants$1,237,762

U01 · FY2024 · TR · contact PI

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants$1,237,967

U01 · FY2023 · TR · contact PI

The New England Precision Medicine Consortium of the All of Us Research Program$9,700,000

OT2 · FY2022 · OD

Return of Genomic Results and Estimating Penetrance in Population-Based Cohorts$1,650,112

R01 · FY2022 · HL · contact PI

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants$1,245,126

U01 · FY2022 · TR · contact PI

Return of Genomic Results and Estimating Penetrance in Population-Based Cohorts$1,832,741

R01 · FY2021 · HL · contact PI

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants$1,385,809

U01 · FY2021 · TR · contact PI

Return of Genomic Results and Estimating Penetrance in Population-Based Cohorts$1,831,528

R01 · FY2020 · HL · contact PI

Experiences and Outcomes in Early Adopters of Predispositional Sequencing$800,000

R01 · FY2020 · HG · contact PI

Return of Genomic Results and Estimating Penetrance in Population-Based Cohorts$1,918,222

R01 · FY2019 · HL · contact PI

Experiences and Outcomes in Early Adopters of Predispositional Sequencing$761,130

R01 · FY2019 · HG · contact PI

Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals$418,729

RF1 · FY2019 · AG · contact PI

Experiences and Outcomes in Early Adopters of Predispositional Sequencing$160,000

R01 · FY2019 · HG · contact PI

Experiences and Outcomes in Early Adopters of Predispositional Sequencing$897,489

R01 · FY2018 · HG · contact PI

Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals$411,239

RF1 · FY2018 · AG · contact PI

Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals$407,457

RF1 · FY2018 · AG · contact PI

Genome Sequence Based Screening for Childhood Risk and Newborn Illness$250,000

U19 · FY2018 · HD · contact PI

ConProject-001$108,168

U19 · FY2018 · HD · contact PI

ConProject-002$36,007

U19 · FY2018 · HD · contact PI

Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,187,163

U19 · FY2017 · HD · contact PI

Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals$114,548

RF1 · FY2017 · AG · contact PI

Integration of Whole Genome Sequencing into Clinical Medicine$2,132,625

U01 · FY2016 · HG · contact PI

Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,175,303

U19 · FY2016 · HD · contact PI

Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals$4,646,052

RF1 · FY2015 · AG · contact PI

Integration of Whole Genome Sequencing into Clinical Medicine$2,370,582

U01 · FY2015 · HG · contact PI

Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,157,495

U19 · FY2015 · HD · contact PI

Integration of Whole Genome Sequencing into Clinical Medicine$2,195,445

U01 · FY2014 · HG · contact PI

Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,153,935

U19 · FY2014 · HD · contact PI

Integration of Whole Genome Sequencing into Clinical Medicine$154,525

U01 · FY2014 · HG · contact PI

Integration of Whole Genome Sequencing into Clinical Medicine$75,000

U01 · FY2014 · HG · contact PI

Integration of Whole Genome Sequencing into Clinical Medicine$2,200,260

U01 · FY2013 · HG · contact PI

Genome Sequence-Based Screening for Childhood Risk and Newborn Illness$1,187,782

U19 · FY2013 · HD · contact PI

Integration of Whole Genome Sequencing into Clinical Medicine$2,410,752

U01 · FY2012 · HG · contact PI

Risk Evaluation and Education for Alzheimer's Disease (REVEAL IV)$584,295

R01 · FY2012 · HG · contact PI

Impact of Direct to Consumer Genetic Testing$329,600

R01 · FY2012 · HG · contact PI

Risk Evaluation and Education for Alzheimer's Disease (REVEAL IV)$596,485

R01 · FY2011 · HG · contact PI

Impact of Direct to Consumer Genetic Testing$368,231

R01 · FY2011 · HG · contact PI

CORE--CLINICAL$669,905

P30 · FY2010 · AG · contact PI

Risk Evaluation and Education for Alzheimer's Disease (REVEAL IV)$601,513

R01 · FY2010 · HG · contact PI

Impact of Direct to Consumer Genetic Testing$411,045

R01 · FY2010 · HG · contact PI

Characterizing and Communicating Genetic Risk for Alzheimer's Disease$190,185

K24 · FY2010 · AG · contact PI

CORE--CLINICAL$718,684

P30 · FY2009 · AG · contact PI

Risk Evaluation and Education for Alzheimer's Disease$362,180

R01 · FY2009 · HG · contact PI

Characterizing and Communicating Genetic Risk for Alzheimer's Disease$186,785

K24 · FY2009 · AG · contact PI

CORE--CLINICAL$714,933

P30 · FY2008 · AG · contact PI

Risk Evaluation and Education for Alzheimer's Disease$572,870

R01 · FY2008 · HG · contact PI

Characterizing and Communicating Genetic Risk for Alzheimer's Disease$182,330

K24 · FY2008 · AG · contact PI

CORE--CLINICAL$640,738

P30 · FY2007 · AG · contact PI

Risk Evaluation and Education for Alzheimer's Disease$556,158

R01 · FY2007 · HG · contact PI

Characterizing and Communicating Genetic Risk for Alzheimer's Disease$179,173

K24 · FY2007 · AG · contact PI

ALZHEIMER'S DISEASE ANTI-INFLAMMATORY PREVENTION TRIAL (ADAPT)$109,735

M01 · FY2007 · RR · contact PI

ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)$13,543

M01 · FY2007 · RR · contact PI

AGING AND ALZHEIMER'S DISEASE BIOSAMPLE REPOSITORY$10,418

M01 · FY2007 · RR · contact PI

ASSESSMENT MEASURES FOR PRIMARY PREVENTION TRIALS IN ALZHEIMERS DISEASE$9,029

M01 · FY2007 · RR · contact PI

SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$6,946

M01 · FY2007 · RR · contact PI

HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE IN ALZHEIMER'S DISEASE$3,125

M01 · FY2007 · RR · contact PI

MPC-7869 MEASURE OF COGNITION, ACTIVITIES MILD DEMENTIA OF THE ALZHEIMER'S TYPE$1,737

M01 · FY2007 · RR · contact PI

GENETIC RISK ASSESSMENT AND COUNSELING FOR ALZHEIMER'S DISEASE (REVEAL)$1,389

M01 · FY2007 · RR · contact PI

STUDY OF LEUPROLIDE ACETATE DEPOT IN THE TREATMENT OF AD IN MEN$1,042

M01 · FY2007 · RR · contact PI

Risk Evaluation and Education for Alzheimer's Disease$818,240

R01 · FY2006 · HG · contact PI

CORE--CLINICAL$437,799

P30 · FY2006 · AG · contact PI

Characterizing Communicating Genetic Risk Alzheimer's$175,555

K24 · FY2006 · AG · contact PI

ALZHEIMER'S DISEASE ANTI-INFLAMMATORY PREVENTION TRIAL (ADAPT)$142,834

M01 · FY2006 · RR · contact PI

AGING AND ALZHEIMER'S DISEASE BIOSAMPLE REPOSITORY$60,995

M01 · FY2006 · RR · contact PI

GENETIC RISK ASSESSMENT AND COUNSELING FOR ALZHEIMER'S DISEASE (REVEAL)$47,483

M01 · FY2006 · RR · contact PI

ASSESSMENT MEASURES FOR PRIMARY PREVENTION TRIALS IN ALZHEIMERS DISEASE$16,214

M01 · FY2006 · RR · contact PI

SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$14,283

M01 · FY2006 · RR · contact PI

HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE IN ALZHEIMER'S DISEASE$11,196

M01 · FY2006 · RR · contact PI

STUDY OF LEUPROLIDE ACETATE DEPOT IN THE TREATMENT OF AD IN MEN$4,247

M01 · FY2006 · RR · contact PI

ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)$4,247

M01 · FY2006 · RR · contact PI

Risk Evaluation and Education for Alzheimer's Disease$779,277

R01 · FY2005 · HG

ALZHEIMER'S DISEASE ANTI-INFLAMMATORY PREVENTION TRIAL (ADAPT)$188,953

M01 · FY2005 · RR

AGING AND ALZHEIMER'S DISEASE BIOSAMPLE REPOSITORY$69,246

M01 · FY2005 · RR

GENETIC RISK ASSESSMENT AND COUNSELING FOR ALZHEIMER'S DISEASE (REVEAL)$61,511

M01 · FY2005 · RR

SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE$16,207

M01 · FY2005 · RR

ASSESSMENT MEASURES FOR PRIMARY PREVENTION TRIALS IN ALZHEIMERS DISEASE$15,838

M01 · FY2005 · RR

HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE IN ALZHEIMER'S DISEASE$13,628

M01 · FY2005 · RR

Risk Evaluation and Education for Alzheimer's Disease$756,981

R01 · FY2004 · HG

Alzheimer's Disease Anti-inflammatory Prevention Trial$181,197

M01 · FY2004 · RR

Risk Evaluation and Education for Alzheimer's Disease$41,443

R01 · FY2004 · HG

Assessment Measures for Primary Prevention Trials in AD$16,999

M01 · FY2004 · RR

Simvastatin to Slow the Progression of Alzheimer's Disease$7,234

M01 · FY2004 · RR

Pilot Testing of Serum and Beta-Amyloid Levels$6,510

M01 · FY2004 · RR

HIGH DOSE SUPPLEMENTS TO REDUCE HOMOCYSTEINE IN AD$5,786

M01 · FY2004 · RR

Genetic Risk Assessment and Counseling for AD$3,255

M01 · FY2004 · RR

Aging and Alzheimer's Disease BioSample Repository$728

M01 · FY2004 · RR

Risk Evaluation and Education for Alzheimer's Disease$836,390

R01 · FY2003 · HG

GENETIC RISK ASSESSMENT FOR ALZHEIMER'S DISEASE$97,008

R01 · FY2003 · HG

CORE--CLINICAL$0

P30 · FY2002 · AG

CORE--CLINICAL$0

P30 · FY2002 · AG

GENETIC RISK ASSESSMENT FOR ALZHEIMER'S DISEASE$520,500

R01 · FY2001 · HG

CORE--CLINICAL$0

P30 · FY2001 · AG

GENETIC RISK ASSESSMENT FOR ALZHEIMER'S DISEASE$492,121

R01 · FY2000 · HG